Alternative G protein coupling and biased agonism: New insights into melanocortin-4 receptor signalling

Molecular and Cellular Endocrinology

Volumn 331, Issue 2, 2011, Pages 232-240

  Breit, Andreas ^a   Büch, Thomas R H ^a   Boekhoff, Ingrid ^a   Solinski, Hans Jürgen ^a   Damm, Ellen ^a   Gudermann, Thomas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

AGRP; Alternative G protein coupling; Biased agonism; MC4R; Melanocortins; Obesity

Indexed keywords

AGOUTI RELATED PROTEIN; ATTRACTIN; GUANINE NUCLEOTIDE BINDING PROTEIN; MAHOGANOID PROTEIN; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN RECEPTOR ACCESSORY PROTEIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RECEPTOR ACTIVITY MODIFYING PROTEIN; SYNDECAN; UNCLASSIFIED DRUG;

ANOREXIA; BINDING COMPETITION; CALCIUM TRANSPORT; CELLULAR DISTRIBUTION; ENDOCYTOSIS; ENERGY BALANCE; ENERGY EXPENDITURE; FOOD INTAKE; HUMAN; ISOMERIZATION; LIPID RAFT; NONHUMAN; OBESITY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 78650273555     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.07.007     Document Type: Review

References (108)

1. Abankwa D., Vogel H. A FRET map of membrane anchors suggests distinct microdomains of heterotrimeric G proteins. Journal of Cell Science 2007, 120(Pt 16):2953-2962.
2. Angers S., Salahpour A., Bouvier M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annual Review of Pharmacology and Toxicology 2002, 42:409-435.
3. Argyropoulos G., Rankinen T., Bai F., Rice T., Province M.A., Leon A.S., Skinner J.S., Wilmore J.H., Rao D.C., Bouchard C. The agouti-related protein and body fatness in humans. International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2003, 27(2):276-280.
4. Armour S.L., Foord S., Kenakin T., Chen W.J. Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor. Journal of Pharmacological and Toxicological Methods 1999, 42(4):217-224.
5. Balthasar N., Dalgaard L.T., Lee C.E., Yu J., Funahashi H., Williams T., Ferreira M., Tang V., McGovern R.A., Kenny C.D., Christiansen L.M., Edelstein E., Choi B., Boss O., Aschkenasi C., Zhang C.Y., Mountjoy K., Kishi T., Elmquist J.K., Lowell B.B. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 2005, 123(3):493-505.
6. Bewick G.A., Gardiner J.V., Dhillo W.S., Kent A.S., White N.E., Webster Z., Ghatei M.A., Bloom S.R. Post-embryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotype. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2005, 19(12):1680-1682.
7. Biebermann H., Castaneda T.R., van Landeghem F., von Deimling A., Escher F., Brabant G., Hebebrand J., Hinney A., Tschop M.H., Gruters A., Krude H A role for beta-melanocyte-stimulating hormone in human body-weight regulation. Cell Metabolism 2006, 3(2):141-146.
8. Biebermann H., Krude H., Elsner A., Chubanov V., Gudermann T., Gruters A. Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes 2003, 52(12):2984-2988.
9. Breit A., Wolff K., Kalwa H., Jarry H., Buch T., Gudermann T. The natural inverse agonist agouti-related protein induces arrestin-mediated endocytosis of melanocortin-3 and -4 receptors. The Journal of Biological Chemistry 2006, 281(49):37447-37456.
10. Brzoska T., Luger T.A., Maaser C., Abels C., Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews 2008, 29(5):581-602.
11. Buch T.R., Heling D., Damm E., Gudermann T., Breit A. Pertussis toxin-sensitive signaling of melanocortin-4 receptors in hypothalamic GT1-7 cells defines agouti-related protein as a biased agonist. The Journal of Biological Chemistry 2009, 284(39):26411-26420.
12. Buhlmann N., Leuthauser K., Muff R., Fischer J.A., Born W. A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1. Endocrinology 1999, 140(6):2883-2890.
13. Chai B., Li J.Y., Zhang W., Newman E., Ammori J., Mulholland M.W. Melanocortin-4 receptor-mediated inhibition of apoptosis in immortalized hypothalamic neurons via mitogen-activated protein kinase. Peptides 2006, 27(11):2846-2857.
14. Chai B., Li J.Y., Zhang W., Wang H., Mulholland M.W. Melanocortin-4 receptor activation inhibits c-Jun N-terminal kinase activity and promotes insulin signaling. Peptides 2009, 30(6):1098-1104.
15. Chan L.F., Webb T.R., Chung T.T., Meimaridou E., Cooray S.N., Guasti L., Chapple J.P., Egertova M., Elphick M.R., Cheetham M.E., Metherell L.A., Clark A.J. MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(15):6146-6151.
16. Chida D., Nakagawa S., Nagai S., Sagara H., Katsumata H., Imaki T., Suzuki H., Mitani F., Ogishima T., Shimizu C., Kotaki H., Kakuta S., Sudo K., Koike T., Kubo M., Iwakura Y. Melanocortin 2 receptor is required for adrenal gland development, steroidogenesis, and neonatal gluconeogenesis. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(46):18205-18210.
17. Christopoulos G., Perry K.J., Morfis M., Tilakaratne N., Gao Y., Fraser N.J., Main M.J., Foord S.M., Sexton P.M. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Molecular Pharmacology 1999, 56(1):235-242.
18. Cone R.D. The central melanocortin system and energy homeostasis. Trends in Endocrinology and Metabolism: TEM 1999, 10(6):211-216.
19. Creemers J.W., Pritchard L.E., Gyte A., Le Rouzic P., Meulemans S., Wardlaw S.L., Zhu X., Steiner D.F., Davies N., Armstrong D., Lawrence C.B., Luckman S.M., Schmitz C.A., Davies R.A., Brennand J.C., White A. Agouti-related protein is posttranslationally cleaved by proprotein convertase 1 to generate agouti-related protein (AGRP)83-132: interaction between AGRP83-132 and melanocortin receptors cannot be influenced by syndecan-3. Endocrinology 2006, 147(4):1621-1631.
20. Czyzyk T.A., Sikorski M.A., Yang L., McKnight G.S. Disruption of the RIIbeta subunit of PKA reverses the obesity syndrome of Agouti lethal yellow mice. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(1):276-281.
21. Dhillo W.S., Small C.J., Jethwa P.H., Russell S.H., Gardiner J.V., Bewick G.A., Seth A., Murphy K.G., Ghatei M.A., Bloom S.R. Paraventricular nucleus administration of calcitonin gene-related peptide inhibits food intake and stimulates the hypothalamo-pituitary-adrenal axis. Endocrinology 2003, 144(4):1420-1425.
22. Dubern B., Clement K., Pelloux V., Froguel P., Girardet J.P., Guy-Grand B., Tounian P. Mutational analysis of melanocortin-4 receptor, agouti-related protein, and alpha-melanocyte-stimulating hormone genes in severely obese children. The Journal of Pediatrics 2001, 139(2):204-209.
23. Ellacott K.L., Cone R.D. The central melanocortin system and the integration of short- and long-term regulators of energy homeostasis. Recent Progress in Hormone Research 2004, 59:395-408.
24. Elsner A., Tarnow P., Schaefer M., Ambrugger P., Krude H., Gruters A., Biebermann H. MC4R oligomerizes independently of extracellular cysteine residues. Peptides 2006, 27(2):372-379.
25. Fu L.Y., van den Pol A.N. Agouti-related peptide and MC3/4 receptor agonists both inhibit excitatory hypothalamic ventromedial nucleus neurons. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 2008, 28(21):5433-5449.
26. Galandrin S., Oligny-Longpre G., Bonin H., Ogawa K., Gales C., Bouvier M. Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor. Molecular Pharmacology 2008, 74(1):162-172.
27. Galandrin S., Oligny-Longpre G., Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. Trends in Pharmacological Sciences 2007, 28(8):423-430.
28. Gantz I., Miwa H., Konda Y., Shimoto Y., Tashiro T., Watson S.J., DelValle J., Yamada T. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. The Journal of Biological Chemistry 1993, 268(20):15174-15179.
29. Graham M., Shutter J.R., Sarmiento U., Sarosi I., Stark K.L. Overexpression of Agrt leads to obesity in transgenic mice. Nature Genetics 1997, 17(3):273-274.
30. Greenfield J.R., Miller J.W., Keogh J.M., Henning E., Satterwhite J.H., Cameron G.S., Astruc B., Mayer J.P., Brage S., See T.C., Lomas D.J., O'Rahilly S., Farooqi I.S. Modulation of blood pressure by central melanocortinergic pathways. The New England Journal of Medicine 2009, 360(1):44-52.
31. Gunn T.M., Miller K.A., He L., Hyman R.W., Davis R.W., Azarani A., Schlossman S.F., Duke-Cohan J.S., Barsh G.S. The mouse mahogany locus encodes a transmembrane form of human attractin. Nature 1999, 398(6723):152-156.
32. Ha E., Kim M.J., Choi B.K., Rho J.J., Oh D.J., Rho T.H., Kim K.H., Lee H.J., Shin D.H., Yim S.V., Baik H.H., Chung J.H., Kim J.W. Positive association of obesity with single nucleotide polymorphisms of syndecan 3 in the Korean population. The Journal of Clinical Endocrinology and Metabolism 2006, 91(12):5095-5099.
33. Hadley M.E. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides 2005, 26(10):1687-1689.
34. Han S.K., Dong X., Hwang J.I., Zylka M.J., Anderson D.J., Simon M.I. Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the Galpha q/11 pathway. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(23):14740-14745.
35. Helms J.B., Zurzolo C. Lipids as targeting signals: lipid rafts and intracellular trafficking. Traffic (Copenhagen, Denmark) 2004, 5(4):247-254.
36. Hinkle P.M., Sebag J.A. Structure and function of the melanocortin2 receptor accessory protein (MRAP). Molecular and Cellular Endocrinology 2009, 300(1-2):25-31.
37. Hinney A., Hohmann S., Geller F., Vogel C., Hess C., Wermter A.K., Brokamp B., Goldschmidt H., Siegfried W., Remschmidt H., Schafer H., Gudermann T., Hebebrand J. Melanocortin-4 receptor gene: case-control study and transmission disequilibrium test confirm that functionally relevant mutations are compatible with a major gene effect for extreme obesity. The Journal of Clinical Endocrinology and Metabolism 2003, 88(9):4258-4267.
38. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., Gu W., Kesterson R.A., Boston B.A., Cone R.D., Smith F.J., Campfield L.A., Burn P., Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88(1):131-141.
39. Kenakin T. Functional selectivity through protean and biased agonism: who steers the ship?. Molecular Pharmacology 2007, 72(6):1393-1401.
40. Khong K., Kurtz S.E., Sykes R.L., Cone R.D. Expression of functional melanocortin-4 receptor in the hypothalamic GT1-1 cell line. Neuroendocrinology 2001, 74(3):193-201.
41. Leaney J.L. Contribution of Kir3.1, Kir3.2A and Kir3.2C subunits to native G protein-gated inwardly rectifying potassium currents in cultured hippocampal neurons. The European Journal of Neuroscience 2003, 18(8):2110-2118.
42. Leduc M., Breton B., Gales C., Le Gouill C., Bouvier M., Chemtob S., Heveker N Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. The Journal of Pharmacology and Experimental Therapeutics 2009, 331(1):297-307.
43. Lee E.J., Lee S.H., Jung J.W., Lee W., Kim B.J., Park K.W., Lim S.K., Yoon C.J., Baik J.H. Differential regulation of cAMP-mediated gene transcription and ligand selectivity by MC3R and MC4R melanocortin receptors. European Journal of Biochemistry/FEBS 2001, 268(3):582-591.
44. Lee Y.S., Challis B.G., Thompson D.A., Yeo G.S., Keogh J.M., Madonna M.E., Wraight V., Sims M., Vatin V., Meyre D., Shield J., Burren C., Ibrahim Z., Cheetham T., Swift P., Blackwood A., Hung C.C., Wareham N.J., Froguel P., Millhauser G.L., O'Rahilly S., Farooqi I.S. A POMC variant implicates beta-melanocyte-stimulating hormone in the control of human energy balance. Cell Metabolism 2006, 3(2):135-140.
45. Lembo P.M., Grazzini E., Groblewski T., O'Donnell D., Roy M.O., Zhang J., Hoffert C., Cao J., Schmidt R., Pelletier M., Labarre M., Gosselin M., Fortin Y., Banville D., Shen S.H., Strom P., Payza K., Dray A., Walker P., Ahmad S. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nature Neuroscience 2002, 5(3):201-209.
46. Liu X., Thangavel M., Sun S.Q., Kaminsky J., Mahautmr P., Stitham J., Hwa J., Ostrom R.S. Adenylyl cyclase type 6 overexpression selectively enhances beta-adrenergic and prostacyclin receptor-mediated inhibition of cardiac fibroblast function because of colocalization in lipid rafts. Naunyn-Schmiedeberg's Archives of Pharmacology 2008, 377(4-6):359-369.
47. Luquet S., Perez F.A., Hnasko T.S., Palmiter R.D. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science (New York, NY) 2005, 310(5748):683-685.
48. MacNeil D.J., Howard A.D., Guan X., Fong T.M., Nargund R.P., Bednarek M.A., Goulet M.T., Weinberg D.H., Strack A.M., Marsh D.J., Chen H.Y., Shen C.P., Chen A.S., Rosenblum C.I., MacNeil T., Tota M., MacIntyre E.D., Van der Ploeg L.H. The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. European Journal of Pharmacology 2002, 450(1):93-109.
49. Metherell L.A., Chapple J.P., Cooray S., David A., Becker C., Ruschendorf F., Naville D., Begeot M., Khoo B., Nurnberg P., Huebner A., Cheetham M.E., Clark A.J. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nature Genetics 2005, 37(2):166-170.
50. Michel M.C., Alewijnse A.E. Ligand-directed signaling: 50 ways to find a lover. Molecular Pharmacology 2007, 72(5):1097-1099.
51. Milligan G., Canals M., Pediani J.D., Ellis J., Lopez-Gimenez J.F. The role of GPCR dimerisation/oligomerisation in receptor signalling. Ernst Schering Foundation Symposium Proceedings 2006, 2:145-161.
52. Milovic S., Steinecker-Frohnwieser B., Schreibmayer W., Weigl L.G. The sensitivity of G protein-activated K+ channels toward halothane is essentially determined by the C terminus. The Journal of Biological Chemistry 2004, 279(33):34240-34249.
53. Minokoshi Y., Alquier T., Furukawa N., Kim Y.B., Lee A., Xue B., Mu J., Foufelle F., Ferre P., Birnbaum M.J., Stuck B.J., Kahn B.B. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004, 428(6982):569-574.
54. Mountjoy K.G., Kong P.L., Taylor J.A., Willard D.H., Wilkison W.O. Melanocortin receptor-mediated mobilization of intracellular free calcium in HEK293 cells. Physiological Genomics 2001, 5(1):11-19.
55. Muff R., Buhlmann N., Fischer J.A., Born W. An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology 1999, 140(6):2924-2927.
56. Nagle D.L., McGrail S.H., Vitale J., Woolf E.A., Dussault B.J., DiRocco L., Holmgren L., Montagno J., Bork P., Huszar D., Fairchild-Huntress V., Ge P., Keilty J., Ebeling C., Baldini L., Gilchrist J., Burn P., Carlson G.A., Moore K.J. The mahogany protein is a receptor involved in suppression of obesity. Nature 1999, 398(6723):148-152.
57. Newman E.A., Chai B.X., Zhang W., Li J.Y., Ammori J.B., Mulholland M.W. Activation of the melanocortin-4 receptor mobilizes intracellular free calcium in immortalized hypothalamic neurons. The Journal of Surgical Research 2006, 132(2):201-207.
58. Nickolls S.A., Fleck B., Hoare S.R., Maki R.A. Functional selectivity of melanocortin 4 receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational states. The Journal of Pharmacology and Experimental Therapeutics 2005, 313(3):1281-1288.
59. Nijenhuis W.A., Oosterom J., Adan R.A. AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Molecular Endocrinology (Baltimore, MD) 2001, 15(1):164-171.
60. Noon L.A., Franklin J.M., King P.J., Goulding N.J., Hunyady L., Clark A.J. Failed export of the adrenocorticotrophin receptor from the endoplasmic reticulum in non-adrenal cells: evidence in support of a requirement for a specific adrenal accessory factor. The Journal of Endocrinology 2002, 174(1):17-25.
61. Ollmann M.M., Wilson B.D., Yang Y.K., Kerns J.A., Chen Y., Gantz I., Barsh G.S. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science (New York, NY) 1997, 278(5335):135-138.
62. Ono Y., Okano I., Kojima M., Okada K., Kangawa K. Decreased gene expression of adrenomedullin receptor in mouse lungs during sepsis. Biochemical and Biophysical Research Communications 2000, 271(1):197-202.
63. Ostrom R.S., Gregorian C., Drenan R.M., Xiang Y., Regan J.W., Insel P.A. Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase. The Journal of Biological Chemistry 2001, 276(45):42063-42069.
64. Ostrom R.S., Violin J.D., Coleman S., Insel P.A. Selective enhancement of beta-adrenergic receptor signaling by overexpression of adenylyl cyclase type 6: colocalization of receptor and adenylyl cyclase in caveolae of cardiac myocytes. Molecular Pharmacology 2000, 57(5):1075-1079.
65. Patten C.S., Daniels D., Suzuki A., Fluharty S.J., Yee D.K. Structural and signaling requirements of the human melanocortin 4 receptor for MAP kinase activation. Regulatory Peptides 2007, 142(3):111-122.
66. Perez-Oliva A.B., Olivares C., Jimenez-Cervantes C., Garcia-Borron J.C. Mahogunin ring finger-1 (MGRN1) E3 ubiquitin ligase inhibits signaling from melanocortin receptor by competition with Galphas. The Journal of Biological Chemistry 2009, 284(46):31714-31725.
67. Phan L.K., Lin F., LeDuc C.A., Chung W.K., Leibel R.L. The mouse mahoganoid coat color mutation disrupts a novel C3HC4 RING domain protein. The Journal of Clinical Investigation 2002, 110(10):1449-1459.
68. Pontier S.M., Percherancier Y., Galandrin S., Breit A., Gales C., Bouvier M. Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction. The Journal of Biological Chemistry 2008, 283(36):24659-24672.
69. Pritchard L.E., Oliver R.L., McLoughlin J.D., Birtles S., Lawrence C.B., Turnbull A.V., White A. Proopiomelanocortin-derived peptides in rat cerebrospinal fluid and hypothalamic extracts: evidence that secretion is regulated with respect to energy balance. Endocrinology 2003, 144(3):760-766.
70. Pritchard L.E., Turnbull A.V., White A. Pro-opiomelanocortin processing in the hypothalamus: impact on melanocortin signalling and obesity. The Journal of Endocrinology 2002, 172(3):411-421.
71. Ramachandran R., Mihara K., Mathur M., Rochdi M.D., Bouvier M., Defea K., Hollenberg M.D. Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways. Molecular Pharmacology 2009, 76(4):791-801.
72. Rediger A., Tarnow P., Bickenbach A., Schaefer M., Krude H., Gruters A., Biebermann H. Heterodimerization of hypothalamic G-protein-coupled receptors involved in weight regulation. Obesity Facts 2009, 2(2):80-86.
73. Redmann S.M., Argyropoulos G. AgRP-deficiency could lead to increased lifespan. Biochemical and Biophysical Research Communications 2006, 351(4):860-864.
74. Reizes O., Benoit S.C., Strader A.D., Clegg D.J., Akunuru S., Seeley R.J. Syndecan-3 modulates food intake by interacting with the melanocortin/AgRP pathway. Annals of the New York Academy of Sciences 2003, 994:66-73.
75. Reizes O., Clegg D.J., Strader A.D., Benoit S.C. A role for syndecan-3 in the melanocortin regulation of energy balance. Peptides 2006, 27(2):274-280.
76. Reizes O., Lincecum J., Wang Z., Goldberger O., Huang L., Kaksonen M., Ahima R., Hinkes M.T., Barsh G.S., Rauvala H., Bernfield M. Transgenic expression of syndecan-1 uncovers a physiological control of feeding behavior by syndecan-3. Cell 2001, 106(1):105-116.
77. Reversi A., Rimoldi V., Marrocco T., Cassoni P., Bussolati G., Parenti M., Chini B. The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism. The Journal of Biological Chemistry 2005, 280(16):16311-16318.
78. Samama P., Cotecchia S., Costa T., Lefkowitz R.J. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the Ternary Complex Model. The Journal of Biological Chemistry 1993, 268(7):4625-4636.
79. Schioth H.B., Haitina T., Ling M.K., Ringholm A., Fredriksson R., Cerda-Reverter J.M., Klovins J. Evolutionary conservation of the structural, pharmacological, and genomic characteristics of the melanocortin receptor subtypes. Peptides 2005, 26(10):1886-1900.
80. Schonbrunn A. Selective agonism in somatostatin receptor signaling and regulation. Molecular and Cellular Endocrinology 2008, 286(1-2):35-39.
81. Schwencke C., Yamamoto M., Okumura S., Toya Y., Kim S.J., Ishikawa Y. Compartmentation of cyclic adenosine 3', 5'-monophosphate signaling in caveolae. Molecular Endocrinology (Baltimore, MD) 1999, 13(7):1061-1070.
82. Sebag J.A., Hinkle P.M. Opposite effects of the melanocortin-2 (MC2) receptor accessory protein MRAP on MC2 and MC5 receptor dimerization and trafficking. The Journal of Biological Chemistry 2009, 284(34):22641-22648.
83. Sexton P.M., Albiston A., Morfis M., Tilakaratne N. Receptor activity modifying proteins. Cellular Signalling 2001, 13(2):73-83.
84. Shenoy S.K., Lefkowitz R.J. Seven-transmembrane receptor signaling through beta-arrestin. Science's STKE 2005, 2005(308):cm10.
85. Shimizu H., Inoue K., Mori M. The leptin-dependent and -independent melanocortin signaling system: regulation of feeding and energy expenditure. The Journal of Endocrinology 2007, 193(1):1-9.
86. Shutter J.R., Graham M., Kinsey A.C., Scully S., Luthy R., Stark K.L. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes & Development 1997, 11(5):593-602.
87. Simon S., Young T.J., Nickolls S.A. The effect of assay formats on the estimation of melanocortin agonist affinity and efficacy using the operation model of agonism. European Journal of Pharmacology 2009, 615(1-3):33-39.
88. Simons K., Toomre D. Lipid rafts and signal transduction. Nature Reviews: Molecular Cell Biology 2000, 1(1):31-39.
89. Starowicz K., Przewlocki R., Gispen W.H., Przewlocka B. Modulation of melanocortin-induced changes in spinal nociception by mu-opioid receptor agonist and antagonist in neuropathic rats. Neuroreport 2002, 13(18):2447-2452.
90. Sutton G.M., Duos B., Patterson L.M., Berthoud H.R. Melanocortinergic modulation of cholecystokinin-induced suppression of feeding through extracellular signal-regulated kinase signaling in rat solitary nucleus. Endocrinology 2005, 146(9):3739-3747.
91. Suzuki I., Cone R.D., Im S., Nordlund J., Abdel-Malek Z.A. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology 1996, 137(5):1627-1633.
92. Tanabe K., Gamo K., Aoki S., Wada K., Kiyama H. Melanocortin receptor 4 is induced in nerve-injured motor and sensory neurons of mouse. Journal of Neurochemistry 2007, 101(4):1145-1152.
93. Thangavel M., Liu X., Sun S.Q., Kaminsky J., Ostrom R.S. The C1 and C2 domains target human type 6 adenylyl cyclase to lipid rafts and caveolae. Cellular Signalling 2009, 21(2):301-308.
94. Thiboutot D., Sivarajah A., Gilliland K., Cong Z., Clawson G. The melanocortin 5 receptor is expressed in human sebaceous glands and rat preputial cells. The Journal of Investigative Dermatology 2000, 115(4):614-619.
95. Tilakaratne N., Christopoulos G., Zumpe E.T., Foord S.M., Sexton P.M. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. The Journal of Pharmacology and Experimental Therapeutics 2000, 294(1):61-72.
96. Tolle V., Low M.J. In vivo evidence for inverse agonism of Agouti-related peptide in the central nervous system of proopiomelanocortin-deficient mice. Diabetes 2008, 57(1):86-94.
97. Vink T., Hinney A., van Elburg A.A., van Goozen S.H., Sandkuijl L.A., Sinke R.J., Herpertz-Dahlmann B.M., Hebebrand J., Remschmidt H., van Engeland H., Adan R.A. Association between an agouti-related protein gene polymorphism and anorexia nervosa. Molecular Psychiatry 2001, 6(3):325-328.
98. Voisey J., Carroll L., van Daal A. Melanocortins and their receptors and antagonists. Current Drug Targets 2003, 4(7):586-597.
99. Vongs A., Lynn N.M., Rosenblum C.I. Activation of MAP kinase by MC4-R through PI3 kinase. Regulatory Peptides 2004, 120(1-3):113-118.
100. Vossler M.R., Yao H., York R.D., Pan M.G., Rim C.S., Stork P.J. cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 1997, 89(1):73-82.
101. Wachira S.J., Guruswamy B., Uradu L., Hughes-Darden C.A., Denaro F.J. Activation and endocytic internalization of melanocortin 3 receptor in neuronal cells. Annals of the New York Academy of Sciences 2007, 1096:271-286.
102. Wan Y., Huang X.Y. Analysis of the Gs/mitogen-activated protein kinase pathway in mutant S49 cells. The Journal of Biological Chemistry 1998, 273(23):14533-14537.
103. Webb T.R., Clark A.J. Minireview: the melanocortin 2 receptor accessory proteins. Molecular Endocrinology (Baltimore, MD) 2010, 24(3):475-484.
104. Wortley K.E., Anderson K.D., Yasenchak J., Murphy A., Valenzuela D., Diano S., Yancopoulos G.D., Wiegand S.J., Sleeman M.W. Agouti-related protein-deficient mice display an age-related lean phenotype. Cell Metabolism 2005, 2(6):421-427.
105. Wu Q., Howell M.P., Cowley M.A., Palmiter R.D. Starvation after AgRP neuron ablation is independent of melanocortin signaling. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(7):2687-2692.
106. Yang Y.K., Thompson D.A., Dickinson C.J., Wilken J., Barsh G.S., Kent S.B., Gantz I. Characterization of Agouti-related protein binding to melanocortin receptors. Molecular Endocrinology (Baltimore, MD) 1999, 13(1):148-155.
107. Yuyama K., Sekino-Suzuki N., Sanai Y., Kasahara K. Translocation of activated heterotrimeric G protein Galpha(o) to ganglioside-enriched detergent-resistant membrane rafts in developing cerebellum. The Journal of Biological Chemistry 2007, 282(36):26392-26400.
108. Zumpe E.T., Tilakaratne N., Fraser N.J., Christopoulos G., Foord S.M., Sexton P.M. Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. Biochemical and Biophysical Research Communications 2000, 267(1):368-372.